logo
Cleveland Clinic Abu Dhabi collaborates with Cleveland Clinic in the U.S.

Cleveland Clinic Abu Dhabi collaborates with Cleveland Clinic in the U.S.

Zawya16-04-2025

This groundbreaking procedure marks the first of its kind in the world and within the Cleveland Clinic health system
The innovative surgery enabled real-time collaboration between Dr. Ruben Olivares Cleveland Clinic Urologist, supporting remotely from Ohio, and Dr. Waleed A. Hassen, Department Chair of Urology at Cleveland Clinic Abu Dhabi, who managed the on-site surgical execution
Abu Dhabi, United Arab Emirates: Cleveland Clinic Abu Dhabi, part of the M42 group, has achieved a historic milestone in global healthcare. In collaboration with experts from Cleveland Clinic in the U.S., the team performed the world's first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer. Focal therapy is a non-invasive treatment that precisely targets a specific section of the prostate using ultrasound beams, eliminating the need for major surgery or radiation. The Focal-One system enhances this approach with a robotic arm that ensures precise and controlled ultrasound delivery.
The innovative surgery enabled real-time collaboration between Dr. Ruben Olivares, Urologist in the Glickman Urological Institute at Cleveland Clinic, supporting remotely from Ohio, and Dr. Waleed A. Hassen, Department Chair of Urology, at Cleveland Clinic Abu Dhabi, who managed the on-site procedural execution. Lasting approximately one hour, the remote procedure was completed successfully without complications, demonstrating the transformative potential of advanced technology in expanding access to specialized care.
Remote procedure, powered by cutting-edge technology and robust communication networks, offers unparalleled access to specialized surgical expertise, even in remote or underserved regions. By combining local and global expertise, it addresses critical gaps in healthcare equity and training while enabling minimally invasive treatment options, such as focal therapy for prostate cancer. However, widespread access to such advanced procedures remains a significant challenge in many parts of the world.
Commenting on the milestone, Hasan Jasem Al Nowais, Chairman of Cleveland Clinic Abu Dhabi, said: 'This innovative remote procedure is a remarkable feat that presents the possibility to manage complex care needs across borders and close global health inequities. We were delighted to have partnered with our colleagues in the U.S. to set a new standard for transcontinental healthcare.'
H.E. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), said: "Abu Dhabi is rapidly evolving towards establishing one of the world's most intelligent and efficient healthcare systems. Our progress is powered by advanced infrastructure and innovation-driven regulatory frameworks, which enhance healthcare quality and accessibility. Cleveland Clinic Abu Dhabi's achievements mark another milestone in our journey of healthcare excellence, showcasing the sector's commitment to pioneering medical solutions and cutting-edge technologies. This success strengthens our local and global partnerships, reaffirming the Emirate's dedication to safeguarding the health and well-being of our community and beyond."
Highlighting the hospital's leadership in medical innovations, Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi said: 'Cleveland Clinic Abu Dhabi has always been at the forefront of integrating advanced technology with world-class care. Remote procedures represent the future of healthcare, pushing the boundaries of what can be achieved in medicine. This procedure exemplifies our vision of leveraging cutting-edge technology with collaborative expertise to set new benchmarks in patient care. It is exciting to partner with our colleagues in the US to make history and transform patient outcomes on a global scale. The success of this procedure marks a new era in global surgical collaboration. We envision a future where advanced treatments are accessible to patients regardless of location, reducing health disparities and improving outcomes for everyone.'
The journey to this remarkable achievement began in October 2023, when Cleveland Clinic Abu Dhabi introduced the Focal One high-intensity focused ultrasound (HIFU) therapy to patients in Abu Dhabi. Focal One represents a novel approach to treating non-metastatic prostate tumors, utilizing advanced imaging technology to precisely target cancerous cells. This method enables effective tumor treatment while minimizing the risk of side effects.
Dr. Waleed A. Hassen, Department Chair of Urology at Cleveland Clinic Abu Dhabi, explains: "There are many ways to treat prostate cancer, and one of the options is focal therapy. It's a non-invasive procedure where we use a robotically controlled arm to deliver treatment. Once the treatment plan is in place, the machine delivers it precisely. This is proof of principle that we can contour the prostate, design the plan, and execute it remotely. The procedure typically takes about an hour, with the Focal-one screen visible to both the surgical team and the ultrasound team, ensuring shared expertise.
Dr. Ruben Olivares, M.D., Urologist in the Glickman Urological Institute at Cleveland Clinic said: 'We are thrilled to have successfully performed the first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer by working in tandem with our partners at Cleveland Clinic Abu Dhabi. Here at Cleveland Clinic, we use cutting-edge technology, but unfortunately, it's not available in many places throughout the U.S. and in the world. We look forward to expanding the adoption of the latest alternative minimally invasive options and increasing access for patients throughout the world with this first step."
This milestone comes as Cleveland Clinic Abu Dhabi celebrates a decade of excellence in care, making remarkable strides in advancing healthcare through integration of technology. As the hospital continues to explore the potential of remote procedures, the implications stretch far beyond prostate cancer treatment. This success not only opens new pathways for surgical education and collaboration but also drives global accessibility to advanced care.
About Cleveland Clinic Abu Dhabi
Cleveland Clinic Abu Dhabi, part of the M42 group, is a multispecialty hospital on Al Maryah Island in Abu Dhabi, UAE. Cleveland Clinic Abu Dhabi is a unique and unparalleled extension of US-based Cleveland Clinic's model of care, specifically designed to address a range of complex and critical care requirements unique to the Abu Dhabi population. Cleveland Clinic Abu Dhabi has the following Institutes and Departments: Heart, Vascular & Thoracic, Neurology, Digestive Disease, Eye, Respiratory, Critical Care, Oncology, Transplant, Surgical Subspecialties, Medical Subspecialties, Emergency Medicine, Anesthesiology, Pathology & Laboratory Medicine, Imaging, Quality & Patient Safety, Clinical & Nursing, Research and Education Departments. In all, more than 50 medical and surgical specialties are offered at Cleveland Clinic Abu Dhabi.
The campus is also home to a stand-alone and dedicated cancer center, Fatima bint Mubarak Center. The state-of-the-art, facility provides patients with access to diagnostics and treatment options through world- class facilities across 24 clinical departments that include a range of cancer subspecialties and programs: Blood Cancers, Breast Cancers, Endocrine Cancers, Gastrointestinal Cancers, Genitourinary Cancers, Gynecological Cancers, Head and Neck Cancers, Neurological Cancers, Thoracic Cancers, Ophthalmological Cancers and Soft Tissue Cancers among others.
Cleveland Clinic Abu Dhabi provides patients in the region with direct access to the world's best healthcare providers and Cleveland Clinic's unique model of care that includes state-of-the-art amenities and world- class service standards closer to home. M42 is an Abu Dhabi-based, global tech-enabled healthcare company operating at the forefront of medical advancement.
Visit us at www.clevelandclinicabudhabi.ae

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abu Dhabi carries out first robotic surgery to remove appendiceal tumour
Abu Dhabi carries out first robotic surgery to remove appendiceal tumour

TAG 91.1

time4 hours ago

  • TAG 91.1

Abu Dhabi carries out first robotic surgery to remove appendiceal tumour

A 48-year-old patient with a rare appendiceal tumour has become the first in Abu Dhabi to undergo a robotic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). Dr. Yasir Akmal, Staff Physician in the Digestive Disease Institute, led a multi-disciplinary team at Cleveland Clinic Abu Dhabi to perform the complex procedure. It involved the removal of multiple internal organs to prevent the spread of the tumour in the patient's abdomen, and the administration of the HIPEC treatment where heated chemotherapy (42 degrees Celsius) is circulated within the abdominal cavity to eliminate any residual cancer cells. The patient, who initially presented symptoms resembling appendicitis, was undergoing a procedure to remove the organ when the surgeons discovered gelatinous deposits (jelly-like substance) in the abdominal cavity. A subsequent pathology report confirmed the presence of a rare low-grade mucinous neoplasm, a tumour that, if untreated, could spread throughout the abdomen and result in a condition known as pseudomyxoma peritonei or 'jelly belly". Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, highlighted that the "minimally invasive techniques... (helps) improve outcomes and enhance quality of life". According to the official stats, appendiceal tumours account for less than 1 per cent of malignancies worldwide and are found in approximately 1.4 per cent of patients who undergo an appendectomy. Highlighting both the preventive and curative nature of the surgery, Dr. Akmal said that the patient's condition was diagnosed at an advanced but treatable stage, and thanks to the timely intervention of the multidisciplinary team, supported by specialised AI-driven diagnostic tools, the team was able to navigate the process of eliminating the cancer cells in her body with precision.

Cleveland Clinic Abu Dhabi performs UAE's first robotic cytoreductive surgery with HIPEC
Cleveland Clinic Abu Dhabi performs UAE's first robotic cytoreductive surgery with HIPEC

Zawya

time7 hours ago

  • Zawya

Cleveland Clinic Abu Dhabi performs UAE's first robotic cytoreductive surgery with HIPEC

ABU DHABI - Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat a rare appendiceal tumour, in a medical milestone that reinforces Abu Dhabi's position as a global destination for innovative healthcare. The complex procedure, performed on a 48-year-old patient, involved the removal of multiple internal organs to prevent the spread of the tumour in her abdomen. This groundbreaking procedure was led by Dr. Yasir Akmal, Staff Physician in the Digestive Disease Institute at Cleveland Clinic Abu Dhabi and an American Fellowship-trained surgical oncologist, and a multi-disciplinary team. Appendiceal tumours account for less than 1 percent of malignancies worldwide and are found in approximately 1.4 percent of patients who undergo an appendectomy. The patient initially presented symptoms resembling appendicitis, leading to the removal of her appendix. However, during the procedure, her surgeon discovered gelatinous deposits, a jelly-like substance, in the abdominal cavity. A subsequent pathology report confirmed the presence of a rare low-grade mucinous neoplasm, a tumour that, if untreated, could spread throughout the abdomen and result in a condition known as pseudomyxoma peritonei or 'jelly belly." Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said, 'We are pushing the boundaries of robotic surgery and are proud to have used such an advanced technology for a complex procedure like Paola's. Cleveland Clinic Abu Dhabi is a leader in surgical innovation, continuously refining minimally invasive techniques to improve outcomes and enhance quality of life.' Following the tumour removal, HIPEC treatment (Hyperthermic Intraperitoneal Chemotherapy) was administered— a technique where heated chemotherapy (42 degrees Celsius) is circulated within the abdominal cavity for 90 minutes to eliminate any residual cancer cells. Highlighting both the preventive and curative nature of the surgery, Dr. Akmal said that the patient's condition was diagnosed at an advanced but treatable stage, and thanks to the timely intervention of the multidisciplinary team, supported by specialised AI-driven diagnostic tools, the team was able to navigate the process of eliminating the cancer cells in her body with precision.

M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care
M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care

Zawya

time6 days ago

  • Zawya

M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care

Partnership will advance cancer diagnosis, inform treatment decisions, and enable real-time monitoring of disease progression in a more cost-effective and less invasive manner The launch is expected in the latter part of Q2 2025, following the completion of an initial validation study at Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.' R oss Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store